Imugene Limited   Report issue

For profit Phase 1 Phase 2
Founded: Melbourne Australia (2012)

Organization Overview

First Clinical Trial
2016
NCT02795988
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Imugene Limited

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma (Phase 2)

Adenocarcinoma of Lung (Phase 1)

Carcinoma, Large Cell (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Digestive System Neoplasms (Phase 2)

Gastrointestinal Neoplasms (Phase 2)

Lung Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 11